EFT-508
| CAS No. | 1849590-01-7 | Cat. No. | BCP18993 |
| Name | EFT-508 | ||
| Synonyms | EFT 508;EFT508;Tomivosertib; | ||
| Formula | C17H20N6O2 | M. Wt | 340.38 |
| Description | In vitro: eFT508 has a half-maximal inhibitory concentration (IC50) of 1-2 nM against both MNK isoforms in enzyme assays and inhibits the kinase through a reversible, ATP-competitive mechanism of action. eFT508 showed anti-proliferative activity against multiple DLBCL cell lines. In vivo: eFT508 is tested in vivo in 7 subcutaneous human lymphoma xenograft models. Significant anti-tumor activity is observed in the TMD8 and HBL-1 ABC-DLBCL models, both of which harbor activating MyD88 mutations. | ||
| Pathways | MAPK Pathway | ||
| Targets | MNK | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.